Drug Patents owned by Bausch

1. List of Acanya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9078870 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(6 years from now)

US9561208 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(6 years from now)

US10220049 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(6 years from now)

US9504704 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(6 years from now)

US8895070 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(6 years from now)

US10137142 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(6 years from now)

US10624918 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(6 years from now)

US8663699 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Jun, 2029

(6 years from now)

US8288434 BAUSCH Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Aug, 2029

(6 years from now)

Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 23 October, 2008

Treatment: Topical treatment of acne vulgaris in patients 12 years or older; Treatment of acne vulgaris; Topical treatment of acne vulgaris; Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of ACANYA before it's patent expiration?
More Information on Dosage

2. List of Aldara drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7696159 BAUSCH Treatment for basal cell carcinoma
Apr, 2024

(1 year, 2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159

(Pediatric)

BAUSCH Treatment for basal cell carcinoma
Oct, 2024

(1 year, 8 months from now)

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 27 February, 1997

Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines

Dosage: CREAM;TOPICAL

How can I launch a generic of ALDARA before it's patent expiration?
More Information on Dosage

3. List of Aplenzin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7569610 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7241805 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7649019 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7671094 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(3 years from now)

US7645802 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(3 years from now)

US7662407 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7572935 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

US7585897 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(3 years from now)

Drugs and Companies using BUPROPION HYDROBROMIDE ingredient

Market Authorisation Date: 23 April, 2008

Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of APLENZIN before it's patent expiration?
More Information on Dosage

4. List of Arazlo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311482 BAUSCH Topical compositions and methods for treating skin diseases
May, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 18, 2022

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 18 December, 2019

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

How can I launch a generic of ARAZLO before it's patent expiration?
More Information on Dosage

5. List of Bryhali drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 06 November, 2018

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of BRYHALI before it's patent expiration?
More Information on Dosage

6. List of Duobrii drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

US10251895 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(13 years from now)

US10426787 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 25, 2022

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of DUOBRII before it's patent expiration?
More Information on Dosage

7. List of Jublia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214506 BAUSCH Method for treating onychomycosis
Feb, 2026

(3 years from now)

US10828369 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US9877955 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US9566272 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US10512640 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US11213519 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US9861698 BAUSCH Compositions and methods for treating diseases of the nail
Jul, 2030

(7 years from now)

US8039494 BAUSCH Compositions and methods for treating diseases of the nail
Jul, 2030

(7 years from now)

US10105444 BAUSCH Compositions and methods for treating diseases of the nail
Jul, 2030

(7 years from now)

US9302009 BAUSCH Compositions and methods for treating diseases of the nail
Oct, 2030

(7 years from now)

US8486978 BAUSCH Compositions and methods for treating diseases of the nail
Oct, 2030

(7 years from now)

US10828293 BAUSCH Anti-infective methods, compositions, and devices
Oct, 2034

(11 years from now)

US10342875 BAUSCH Stabilized efinaconazole compositions
Oct, 2034

(11 years from now)

US9662394 BAUSCH Stabilized efinaconazole compositions
Oct, 2034

(11 years from now)

US10864274 BAUSCH Stabilized efinaconazole formulations
Oct, 2034

(11 years from now)

US10478601 BAUSCH Applicator
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient

Dosage: SOLUTION;TOPICAL

How can I launch a generic of JUBLIA before it's patent expiration?
More Information on Dosage

8. List of Locoid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7981877 BAUSCH Stabilized steroid composition and method for its preparation
Jan, 2025

(1 year, 11 months from now)

US7378405 BAUSCH Stabilized steroid composition and method for its preparation
Dec, 2026

(3 years from now)

Drugs and Companies using HYDROCORTISONE BUTYRATE ingredient

Market Authorisation Date: 18 May, 2007

Treatment: NA

Dosage: LOTION;TOPICAL

How can I launch a generic of LOCOID before it's patent expiration?
More Information on Dosage

9. List of Luzu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9199977 BAUSCH Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
Sep, 2033

(10 years from now)

US9453006 BAUSCH Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
Sep, 2033

(10 years from now)

US9012484 BAUSCH Crystal and pharmaceutical preparation containing the same crystal
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980931 BAUSCH Method of evaluating pharmaceutical preparation containing luliconazole and index substance
Apr, 2034

(11 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Market Authorisation Date: 14 November, 2013

Treatment: Treatment of fungal infections

Dosage: CREAM;TOPICAL

More Information on Dosage

10. List of Solodyn drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252776 BAUSCH Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(2 years from now)

US7790705 BAUSCH Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(2 years from now)

US8722650 BAUSCH Extended-release minocycline dosage forms
Jun, 2025

(2 years from now)

US8268804 BAUSCH Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(2 years from now)

US7919483 BAUSCH Method for the treatment of acne
Mar, 2027

(4 years from now)

US7541347 BAUSCH Minocycline oral dosage forms for the treatment of acne
Apr, 2027

(4 years from now)

US7544373 BAUSCH Minocycline oral dosage forms for the treatment of acne
Apr, 2027

(4 years from now)

US9192615 BAUSCH Method for the treatment of acne and certain dosage forms thereof
Nov, 2031

(8 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 May, 2006

Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SOLODYN before it's patent expiration?
More Information on Dosage

11. List of Vanos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7794738 BAUSCH Compositions and methods for enhancing corticosteroid delivery
Sep, 2022

(4 months ago)

US7220424 BAUSCH Compositions and methods for enhancing corticosteroid delivery
Jan, 2023

(20 days ago)

US8232264 BAUSCH Compositions and methods for enhancing corticosteroid delivery
Mar, 2023

(a month from now)

Drugs and Companies using FLUOCINONIDE ingredient

Market Authorisation Date: 11 February, 2005

Treatment: Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older

Dosage: CREAM;TOPICAL

How can I launch a generic of VANOS before it's patent expiration?
More Information on Dosage

12. List of Xerese drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7223387 BAUSCH Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
Nov, 2022

(2 months ago)

Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older); Combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older)

Dosage: CREAM;TOPICAL

More Information on Dosage

13. List of Zyclara drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598196 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
Aug, 2029

(6 years from now)

US10238645 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Aug, 2029

(6 years from now)

US8222270 BAUSCH 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod
Dec, 2029

(6 years from now)

US10238644 BAUSCH 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Dec, 2029

(6 years from now)

US11318130 BAUSCH 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Dec, 2029

(6 years from now)

US8299109 BAUSCH Method of treating actinic keratosis with 3.75% imiquimod cream
Dec, 2029

(6 years from now)

US8236816 BAUSCH 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
Dec, 2029

(6 years from now)

US10918635 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Apr, 2030

(7 years from now)

US11202752 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
Apr, 2030

(7 years from now)

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 25 March, 2010

Treatment: Treatment of genital warts; Treatment of perianal warts; Treatment of actinic keratosis

Dosage: CREAM;TOPICAL

How can I launch a generic of ZYCLARA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic